First Republic Capital

FSD Pharma congratulates partner Canntab on launch of research partnership with leading orthopaedic surgeon Dr. Don Garbuz, M.D.

TORONTO, Dec. 5, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) today congratulated strategic partner Canntab Therapeutics Limited (“Canntab”) on the launch of a research partnership with leading orthopaedic surgeon Dr. Don Garbuz, M.D. Dr. Garbuz will be the lead investigator on a clinical research study at the University of British Columbia subject to the University’s approval that aims to show the potential for reduction or elimination of the use of opiates in orthopaedic patients using Canntab’s sustained release tablets. Canntab will create the tablets for the study in Cobourg, Ontario with FSD Pharma in furtherance of their collaboration and license agreement dated September 17, 2018.

Vanadium One Strengthens its Board of Directors and Management Team

TORONTO, CANADA / ACCESSWIRE / November 26, 2018 / Vanadium One Energy Corp. (TSX-V: VONE), continues to strengthen its Board of Directors and management team with the appointment of two industry leaders to its Board of Directors. The Company is please to announce that Mr. Mark Brennan and Mr. Casper Groenewald have joined the Board of Directors and Mr. Brennan will become the Company’s first Chairman. Messrs. Brendan and Groenewald were instrumental in building Largo Resources and its Maracas Menchen Mine. They lead an impressive slate of proposed Directors for election at the Company’s next AGM, to be held on December 18, 2018.

FSD Pharma Appoints Top GW Pharmaceuticals Executive, Rupert Haynes, as Chief Executive Officer

TORONTO, Nov. 26, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today the appointment of Rupert Haynes as Chief Executive Officer. Mr. Haynes is a highly accomplished healthcare executive with nearly three decades of global pharmaceutical experience having most recently held the position of Head of Global Marketing at GW Pharmaceuticals (Nasdaq: GWPH) in the United Kingdom. In his new role with FSD Pharma, Mr. Haynes will continue to work out of the United Kingdom, which will support FSD Pharma’s strategy of expanding its global footprint. Interim CEO and Co-chairman of the board, Dr. Raza Bokhari will remain in place as CEO until Mr. Haynes officially assumes the role.

FSD Pharma Receives License to Sell to Other Licensed Producers

TORONTO, Nov. 13, 2018 /CNW/ – FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that the license of its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”) under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) has been migrated to the Cannabis Act and its regulations, effective November 8, 2018. The issuance of the new cannabis license includes the ability to sell cannabis to other licensed producers in accordance with subsection 11(5) of the Cannabis Regulations.

Mission Ready Provides Update on Unifire Acquisition

VANCOUVER, British Columbia, Nov. 09, 2018 (GLOBE NEWSWIRE) — Mission Ready Solutions Inc. (“Mission Ready” or the “Company”) (TSXV:MRS) wishes to provide a general update on the Company’s progress, including (i) the non-binding letter of intent to acquire (the “Acquisition”) Unifire, Inc.; (ii) the engagement letter (the “Engagement Letter”) with Bay Crest Partners, LLC (the “Agent”); (iii) the fee agreement (the “Fee Agreement”) with Celadon Financial Group, LLC (“Celadon”); and (iv) the Foreign Military Distribution Agreement (the “Distribution Agreement”) first announced on September 6, 2017, with subsequent related announcements provided on September 20, 2017, November 30, 2017, and December 29, 2017.

Canada House Clinics Partners with Peak Pharma Solutions

TORONTO, Nov. 08, 2018 (GLOBE NEWSWIRE) — Canada House Clinics, the clinic division of Canada House Wellness Group Inc (“Canada House” or the “Company”) (CSE: CHV), is pleased to announce it has entered into a strategic partnership with Peak Pharma Solutions, leveraging its new clinic branding and organizational changes to position itself for accelerated growth.